<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Canadian Pharmacy Blog &#187; Main</title>
	<atom:link href="http://annpharmacy.com/blog/category/main/feed" rel="self" type="application/rss+xml" />
	<link>http://annpharmacy.com/blog</link>
	<description>Health, Diseases, Drugs &#38; medications, Online canadian pharmacy</description>
	<lastBuildDate>Wed, 28 Jul 2010 16:32:20 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.1-beta1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Factor VIIa (Recombinant) For Acquired Hemophilia</title>
		<link>http://annpharmacy.com/blog/main/factor-viia-recombinant-for-acquired-hemophilia.html</link>
		<comments>http://annpharmacy.com/blog/main/factor-viia-recombinant-for-acquired-hemophilia.html#comments</comments>
		<pubDate>Tue, 27 Jul 2010 16:32:19 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Acquired Hemophilia]]></category>
		<category><![CDATA[Recombinant]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=458</guid>
		<description><![CDATA[
Coagulation factor VIIa (recombinant) (NovoSeven, Novo Nordisk) is the first recombinant therapy to be approved for the treatment of bleeding episodes and for the prevention of bleeding in patients with acquired hemophilia who are undergoing invasive surgical procedures.
First introduced in 1999, NovoSeven is currently indicated for the treatment of bleeding episodes in hemophilia A or [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/main/factor-viia-recombinant-for-acquired-hemophilia.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Posaconazole for Candidal Infections</title>
		<link>http://annpharmacy.com/blog/main/posaconazole-for-candidal-infections.html</link>
		<comments>http://annpharmacy.com/blog/main/posaconazole-for-candidal-infections.html#comments</comments>
		<pubDate>Mon, 26 Jul 2010 16:32:18 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Candidal Infections]]></category>
		<category><![CDATA[Posaconazole]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=456</guid>
		<description><![CDATA[Posaconazole oral suspension (Noxafil, Schering-Plough) is now approved for patients with oropharyngeal candi-diasis, including infections refractory to itraconazole and/or fluconazole.
cheap celebrex
]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/main/posaconazole-for-candidal-infections.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Adalimumab May Lessen Joint Damage in Psoriatic Arthritis</title>
		<link>http://annpharmacy.com/blog/main/adalimumab-may-lessen-joint-damage-in-psoriatic-arthritis.html</link>
		<comments>http://annpharmacy.com/blog/main/adalimumab-may-lessen-joint-damage-in-psoriatic-arthritis.html#comments</comments>
		<pubDate>Sat, 24 Jul 2010 16:32:16 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Adalimumab]]></category>
		<category><![CDATA[Psoriatic Arthritis]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=452</guid>
		<description><![CDATA[
The FDA has approved an expanded indication for the human monoclonal antibody adalimumab (Humira, Abbott) that includes inhibiting structural joint damage and improving physical function in patients with psoriatic arthritis (PsA). This indication is in addition to the approval for PsA that was granted in October 2005.
This product is also approved for moderate-to-severe rheumatoid arthritis [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/main/adalimumab-may-lessen-joint-damage-in-psoriatic-arthritis.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Should Memantine Be Given Across the Board?</title>
		<link>http://annpharmacy.com/blog/main/should-memantine-be-given-across-the-board.html</link>
		<comments>http://annpharmacy.com/blog/main/should-memantine-be-given-across-the-board.html#comments</comments>
		<pubDate>Sun, 11 Jul 2010 11:37:01 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Memantine]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=398</guid>
		<description><![CDATA[Arbitrarily dividing patients with Alzheimer&#8217;s disease (AD) into groups according to disease severity may keep some of them from benefiting from treatment, suggest findings from a meta-analysis study.
Researchers from Baylor College of Medicine, the University of Rochester, the University of South Florida (Tampa), and Forest Laboratories found that memantine (Namenda, Forest), which is usually reserved [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/main/should-memantine-be-given-across-the-board.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tiagabine (Gabitril) Helps Reduce Cocaine Use</title>
		<link>http://annpharmacy.com/blog/main/tiagabine-gabitril-helps-reduce-cocaine-use.html</link>
		<comments>http://annpharmacy.com/blog/main/tiagabine-gabitril-helps-reduce-cocaine-use.html#comments</comments>
		<pubDate>Thu, 24 Jun 2010 11:36:53 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Cocaine Use]]></category>
		<category><![CDATA[Tiagabine]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=378</guid>
		<description><![CDATA[It came as a bit of a surprise, but tiagabine (Gabitril, Cephalon) was found to be superior to gabapentin (Neurontin, Pfizer) in reducing cocaine use among cocaine-dependent patients who were taking methadone.
Researchers at Yale University and the University of Arkansas in Little Rock randomly assigned 76 cocaine-dependent men to receive tiagabine 24 mg/day, gabapentin 2,400 [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/main/tiagabine-gabitril-helps-reduce-cocaine-use.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Needle-less Coagulation Factor Replacement Kit</title>
		<link>http://annpharmacy.com/blog/main/needle-less-coagulation-factor-replacement-kit.html</link>
		<comments>http://annpharmacy.com/blog/main/needle-less-coagulation-factor-replacement-kit.html#comments</comments>
		<pubDate>Tue, 22 Jun 2010 11:36:51 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Kit]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=374</guid>
		<description><![CDATA[The FDA has approved four enhancements for Wyeth&#8217;s BeneFIX Coagulation Factor IX (Recombinant): a 2,000 IU vial, a needle-less reconstitution device, a pre-filled syringe, and a reduced volume of diluent.
The R2 Kit is easier to prepare than the original BeneFIX kit. BeneFIX replaces clotting factor IX to stop or prevent bleeding in people with hemophilia [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/main/needle-less-coagulation-factor-replacement-kit.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Conivaptan HCl (Vaprisol) For Hypervolemic Hyponatremia</title>
		<link>http://annpharmacy.com/blog/main/conivaptan-hcl-vaprisol-for-hypervolemic-hyponatremia.html</link>
		<comments>http://annpharmacy.com/blog/main/conivaptan-hcl-vaprisol-for-hypervolemic-hyponatremia.html#comments</comments>
		<pubDate>Sat, 19 Jun 2010 11:36:50 +0000</pubDate>
		<dc:creator>John Mitchell</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Hypervolemic Hyponatremia]]></category>
		<category><![CDATA[Vaprisol]]></category>

		<guid isPermaLink="false">http://annpharmacy.com/blog/?p=372</guid>
		<description><![CDATA[Conivaptan HCl injection (Vaprisol, Astellas Pharma US) has been approved for the intravenous treatment of hyper-volemic hyponatremia in hospitalized patients. The drug was originally approved for euvolemic hyponatremia in December 2005.
This arginine vasopressin receptor antagonist is the first drug indicated specifically for the treatment of both euvolemic and hypervolemic hypo-natremia. These potentially life-threatening conditions occur [...]]]></description>
		<wfw:commentRss>http://annpharmacy.com/blog/main/conivaptan-hcl-vaprisol-for-hypervolemic-hyponatremia.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
